Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards
Oragenics, Inc. (NYSE:OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical
Oragenics is testing a new medicine on a small group of people, which is progress. But the company also got a warning from the stock exchange saying it needs to fix some rules or its stock listing could be in trouble.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.